Healthcare.gov, the main entry point for people seeking insurance in 38 states served by the federal exchange, features three new window-shopping features.
The U.S. Food and Drug Administration ha approved Octapharma’s NUWIQ, antihemophilic factor (recombinant), an intravenous therapy for adults and children living with hemophilia A.
To make the U.S.healthcare system more accountable, the federal government continues to release Medicare claims and payment information.
The U.S. Food and Drug Administration has approved Belbuca (buprenorphine) buccal film for patients with severe chronic pain.
The U.S. Senate Appropriations Committee approved the fiscal year 2016 appropriations bill to fund the U.S. Food and Drug Administration but at levels far below what President Obama requested.
The U.S. Food and Drug Administration (FDA) approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of advanced melanoma.
The Centers for Medicare and Medicaid Services issued final rules detailing how it will pay for services provided to Medicare beneficiaries in 2016.
In the Fall 2015 issue of BioSupply Trends Quarterly, the feature "The Perfect Storm for Patient-Centered Clinical Trials" included an incorrect statistic. Here is the correction.
Statin-triggered autoimmune myopathy can occur in rare instances where muscle-related symptoms fail to resolve following stoppage of the medication.
Hailed as a major advancement in the fight against skin cancer, the U.S. Food and Drug Administration (FDA) has approved a new immune-based therapy for treating metastatic melanoma.
President Obama signed a bill into law that will compensate patients for participating in clinical studies of rare diseases.
The U.S. Food and Drug Administration approved the first replacement therapy for hereditary factor X deficiency, coagulation factor X (Coagadex, Bio Products Laboratory), derived from human plasma.